- In a regulatory 8-K filing, on June 30, Dare Bioscience Inc (NASDAQ:DARE) entered into an agreement with the Bill & Melinda Gates Foundation for a new grant of up to $48.95 million for DARE-LARC1, its investigational user-controlled, long-acting reversible contraceptive.
- The Grant will support technology development and preclinical activities to advance DARE-LARC1 toward clinical testing in humans from June 30 to November 1, 2026.
- The company will receive an initial payment of $11.45 million in July 2021.
- Additional payments are contingent upon the DARE-LARC1 program’s achievement of specified milestones.
- Price Action: DARE shares are up 23.4% at $1.87 during the market session on the last check Wednesday.
Ford Says Electric Crate Motors That Can Replace Combustion Engines In Old, New Vehicles Are Sold Out
Ford Motor Company’s (NYSE: F) crate motor that can be used to retrofit internal combustion engine vehicles with electric drivetrains is already sold out.
